Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triple Study: Triple Combination Therapy After Surgery for Chronic Subdural Hematoma
jRCTs031240007Recruiting
- Sponsor
- University of Tsukuba Hospital
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of oreongsan, carbazochrome sodium sulfonate and tranexamic acid in Chronic subdural haematoma (CSDH) (2 arms), sponsored by University of Tsukuba Hospital. Primary endpoint: Hematoma recurrence rate. Started May 2024; status: recruiting.
02
Drugs
oreongsancarbazochrome sodium sulfonatetranexamic acid
03
Conditions
Chronic subdural haematoma (CSDH)
Beyond the preview
Go deeper on jRCTs031240007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031240007.